Compare Medtronic PLC (MDT) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs MPLX LP — how do they compare? Medtronic PLC trades at $82.6 (market cap $106.61B), while MPLX LP trades at $56.76 (market cap $57.97B). The key difference: Medtronic PLC is the larger of the two by market cap, and MPLX LP pays the higher dividend (7.54%). Which is the better fit depends on your goals.
| MDT | MPLX | |
|---|---|---|
Market Cap | $106.61B | $57.97B |
Sector | Health | Technology |
52-Week High | $105.35 | $59.17 |
52-Week Low | $73.75 | $47.80 |
Enterprise Value | $125.36B | $82.60B |
Dividend Yield | 3.46% | 7.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
MPLX trades at $57.13, up 0.12% today, with a bullish technical signal from moving averages and a consensus analyst price target of $60.00. The company reported strong profitability with a 41.24% net income margin in 2025 and has beaten earnings estimates in two of the last three quarters. Recent news highlights its resilient midstream model and attractive dividend yield.
The outlook for MPLX is positive, supported by stable cash flows, a high dividend yield, and analyst optimism. Key risks include exposure to energy market volatility and a recent earnings miss. The stock offers value with a P/E of 12.35 and strong institutional buy ratings, but investors should monitor execution on growth projects and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
